A Meeting of Mind Menders

Strategic partnership targets mABs for neurodegenerative diseases

Angus Stewart | 07/23/2021 | Quick Read

GlaxoSmithKline and Alector have announced a global partnership to develop and commercialize two monoclonal antibodies: AL001 and AL101. The mAbs are designed to elevate progranulin (PGRN) – a key regulator of immune activity in the brain that has genetic links to multiple neurodegenerative disorders (1). PGRN is considered one of the most attractive targets for new immuno-neurology treatments.

Enrolment is currently underway for a phase III trial of AL001 in people at risk of frontotemporal dementia due to a PGRN gene mutation. AL001 is also being studied in trials of patients with symptomatic frontotemporal dementia with a mutation in the C9orf72 gene, as well as in patients with amyotrophic lateral sclerosis. Meanwhile, AL101 is being investigated to treat patients with more prevalent neurodegenerative diseases, including Parkinson’s and Alzheimer’s.

Email*

Choose a password*

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the "Small Molecule" field I want to stay up to date with the Cell and Gene field I want to stay up to date with the Bioprocessing field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Business & Regulation Drug Discovery

GlaxoSmithKline, “GSK and Alector announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases” (2021). Available at: https://bit.ly/3qORbeo

Angus Stewart

Associate Editor of The Medicine Maker

Between studying for my English undergrad and Publishing master's degrees I was out in Shanghai, teaching, learning, and getting extremely lost. Now I'm expanding my mind down a rather different rabbit hole: the pharmaceutical industry. Outside of this job I read mountains of fiction and philosophy, and I must say, it's very hard to tell who's sharper: the literati, or the medicine makers.